Lilly’s Verzenio Fails In KRAS Mutated Lung Cancer
The series of setbacks continues for
Eli Lilly and Company LLY as the company announced that its phase III JUNIPER study failed to meet the primary endpoint. The study was evaluating Verzenio in advanced non-small lung cancer ("NSCLC") with KRAS mutation. Shares fell 1% on Tuesday after the announcement.
Verzenio received approval for treating metastatic breast cancer last month in patients where the disease progressed after platinum-based chemotherapy.
Lilly’s shares are up 17.1% so far this year, slightly underperforming the industry’s gain of 18.3% in the period.